SK Hynix vs Zoetis Inc — how do they compare? SK Hynix trades at $169.62 (market cap $891.31B), while Zoetis Inc trades at $74.76 (market cap $30.20B). The key difference: SK Hynix is far larger — about 29.5× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold SK Hynix for 10 Days and Zoetis Inc for 70 Days on average.
| SKHY | ZTS | |
|---|---|---|
Market Cap | $891.31B | $30.20B |
Volume | 22,268,296 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $198.63 | $147.53 |
52-Week Low | $126.79 | $69.09 |
Typical Hold Time | 10 Days | 70 Days |
Enterprise Value | $841.45B | $37.76B |
Dividend Yield | 0.06% | 2.9% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
SK hynix is a South Korean semiconductor company that manufactures memory products, including DRAM and NAND flash. Its high-bandwidth memory (HBM) products are designed for high-performance computing and AI applications.
Read more on SKHY →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →